抑制人类免疫缺陷病毒感染细胞融合的抗体可结合病毒包膜gp120的一段24个氨基酸的序列。
Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.
作者信息
Rusche J R, Javaherian K, McDanal C, Petro J, Lynn D L, Grimaila R, Langlois A, Gallo R C, Arthur L O, Fischinger P J
机构信息
Repligen Corporation, Cambridge, MA 02139.
出版信息
Proc Natl Acad Sci U S A. 1988 May;85(9):3198-202. doi: 10.1073/pnas.85.9.3198.
Abstract
Antisera to recombinant human immunodeficiency virus (HIV) proteins containing the entire envelope, gp160, or the central portion of the envelope, PB1, can inhibit fusion of virally infected cells in culture. This fusion inhibition is HIV-variant specific--that is, anti-gp160-IIIB inhibits fusion of isolate HTLV-IIIB-infected cells but not of isolate HTLV-IIIRF-infected cells. Both anti-gp160 and anti-PB1 are completely blocked in fusion inhibition activity by the addition of PB1 protein. A 24-amino acid peptide (RP135, amino acids 307-330) completely blocks fusion inhibition activity of both antisera and also blocks the activity of serum from a chimpanzee infected with HTLV-IIIB. Thus, the principal epitope that elicits fusion-inhibiting antibodies is located in the central portion of gp120.
摘要
针对包含完整包膜蛋白gp160或包膜中央部分PB1的重组人类免疫缺陷病毒（HIV）蛋白的抗血清，可抑制培养物中病毒感染细胞的融合。这种融合抑制具有HIV变体特异性，即抗gp160-IIIB可抑制分离株HTLV-IIIB感染细胞的融合，但不能抑制分离株HTLV-IIIRF感染细胞的融合。添加PB1蛋白后，抗gp160和抗PB1的融合抑制活性均被完全阻断。一种24个氨基酸的肽（RP135，氨基酸307 - 330）可完全阻断两种抗血清的融合抑制活性，也可阻断感染HTLV-IIIB的黑猩猩血清的活性。因此，引发融合抑制抗体的主要表位位于gp120的中央部分。
相似文献
1
Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.抑制人类免疫缺陷病毒感染细胞融合的抗体可结合病毒包膜gp120的一段24个氨基酸的序列。
Proc Natl Acad Sci U S A. 1988 May;85(9):3198-202. doi: 10.1073/pnas.85.9.3198.
2
Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.具有保守结构的1型人类免疫缺陷病毒中和表位在实验感染的黑猩猩中引发早期型特异性抗体。
Proc Natl Acad Sci U S A. 1988 Jun;85(12):4478-82. doi: 10.1073/pnas.85.12.4478.
3
4
Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120.针对人类免疫缺陷病毒1型gp120假定CD4结合域的单克隆抗体的产生与特性分析
J Virol. 1989 Sep;63(9):3579-85. doi: 10.1128/JVI.63.9.3579-3585.1989.
5
Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.用人免疫缺陷病毒env编码的合成肽抗体进行型特异性中和
Proc Natl Acad Sci U S A. 1988 Mar;85(6):1932-6. doi: 10.1073/pnas.85.6.1932.
6
Purification and characterization of the external envelope glycoprotein from two human immunodeficiency virus type 1 variants, HTLV-IIIB and HTLV-IIIRF.两种1型人类免疫缺陷病毒变体HTLV-IIIB和HTLV-IIIRF的外膜糖蛋白的纯化与特性分析
J Virol. 1988 Jul;62(7):2258-64. doi: 10.1128/JVI.62.7.2258-2264.1988.
7
8
Specificity and function of the individual amino acids of an important determinant of human immunodeficiency virus type 1 that induces neutralizing activity.诱导中和活性的人类免疫缺陷病毒1型重要决定簇中单个氨基酸的特异性和功能。
J Gen Virol. 1989 Jun;70 ( Pt 6):1505-12. doi: 10.1099/0022-1317-70-6-1505.
9
Isolate- and group-specific immune responses to the envelope protein of human immunodeficiency virus induced by a live recombinant vaccinia virus in macaques.
AIDS Res Hum Retroviruses. 1989 Feb;5(1):23-32. doi: 10.1089/aid.1989.5.23.
10
Restricted neutralization of divergent HTLV-III/LAV isolates by antibodies to the major envelope glycoprotein.针对主要包膜糖蛋白的抗体对不同的HTLV-III/LAV分离株的中和作用受限。
Haematol Blood Transfus. 1987;31:414-22. doi: 10.1007/978-3-642-72624-8_89.
引用本文的文献
1
Tackling Infectious Diseases in the Caribbean and South America: Epidemiological Insights, Antibiotic Resistance, Associated Infectious Diseases in Immunological Disorders, Global Infection Response, and Experimental Anti-Idiotypic Vaccine Candidates Against Microorganisms of Public Health Importance.应对加勒比地区和南美洲的传染病：流行病学见解、抗生素耐药性、免疫紊乱中的相关传染病、全球感染应对措施以及针对具有公共卫生重要性的微生物的实验性抗独特型疫苗候选物。
Microorganisms. 2025 Jan 27;13(2):282. doi: 10.3390/microorganisms13020282.
2
Inducible cell lines producing replication-defective human immunodeficiency virus particles containing envelope glycoproteins stabilized in a pretriggered conformation.可诱导细胞系产生含有以预触发构象稳定化的包膜糖蛋白的复制缺陷型人类免疫缺陷病毒颗粒。
J Virol. 2024 Dec 17;98(12):e0172024. doi: 10.1128/jvi.01720-24. Epub 2024 Nov 7.
3
Concurrent Exposure of Neutralizing and Non-neutralizing Epitopes on a Single HIV-1 Envelope Structure.单一 HIV-1 包膜结构上中和和非中和表位的同时暴露。
Front Immunol. 2019 Jul 5;10:1512. doi: 10.3389/fimmu.2019.01512. eCollection 2019.
4
Survivors Remorse: antibody-mediated protection against HIV-1.幸存者的悔恨：抗体介导的针对HIV-1的保护作用。
Immunol Rev. 2017 Jan;275(1):271-284. doi: 10.1111/imr.12510.
5
In silico Analysis of HIV-1 Env-gp120 Reveals Structural Bases for Viral Adaptation in Growth-Restrictive Cells.HIV-1包膜糖蛋白gp120的计算机模拟分析揭示了病毒在生长受限细胞中适应性的结构基础。
Front Microbiol. 2016 Feb 9;7:110. doi: 10.3389/fmicb.2016.00110. eCollection 2016.
6
Structural basis of clade-specific HIV-1 neutralization by humanized anti-V3 monoclonal antibody KD-247.人源化抗V3单克隆抗体KD-247对特定进化枝HIV-1中和作用的结构基础
FASEB J. 2015 Jan;29(1):70-80. doi: 10.1096/fj.14-252262. Epub 2014 Oct 28.
7
Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection.针对多种HIV-1亚型V1V2区域的疫苗诱导IgG抗体与HIV-1感染风险降低相关。
PLoS One. 2014 Feb 4;9(2):e87572. doi: 10.1371/journal.pone.0087572. eCollection 2014.
8
Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design.基于HIV-1抗体的疫苗设计中的抗原性和免疫原性。
J AIDS Clin Res. 2012;S8:3. doi: 10.4172/2155-6113. Epub 2012 Mar 22.
9
Structural dynamics of HIV-1 envelope Gp120 outer domain with V3 loop.HIV-1 包膜 Gp120 外域与 V3 环的结构动力学。
PLoS One. 2012;7(5):e37530. doi: 10.1371/journal.pone.0037530. Epub 2012 May 18.
10
Phages and HIV-1: from display to interplay.噬菌体与人类免疫缺陷病毒1型：从展示到相互作用
Int J Mol Sci. 2012;13(4):4727-4794. doi: 10.3390/ijms13044727. Epub 2012 Apr 13.
本文引用的文献
1
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.CD4（T4）抗原是艾滋病逆转录病毒受体的重要组成部分。
Nature. 1984;312(5996):763-7. doi: 10.1038/312763a0.
2
Induction of anti-HIV neutralizing antibodies by synthetic peptides.合成肽诱导抗HIV中和抗体
EMBO J. 1986 Nov;5(11):3065-71. doi: 10.1002/j.1460-2075.1986.tb04607.x.
3
Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein.HTLV-III/LAV包膜糖蛋白诱导依赖CD4的细胞融合。
Nature. 1986;323(6090):725-8. doi: 10.1038/323725a0.
4
Mutational analysis of the signal-anchor domain of influenza virus neuraminidase.流感病毒神经氨酸酶信号锚定结构域的突变分析
Proc Natl Acad Sci U S A. 1987 Jan;84(1):1-5. doi: 10.1073/pnas.84.1.1.
5
Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody.预防人类免疫缺陷病毒感染的前景：纯化的120 kDa包膜糖蛋白可诱导中和抗体。
Proc Natl Acad Sci U S A. 1986 Sep;83(18):7023-7. doi: 10.1073/pnas.83.18.7023.
6
Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity.人类嗜T淋巴细胞病毒III型/淋巴腺病相关病毒包膜在合胞体形成及细胞病变中的作用。
Nature. 1986;322(6078):470-4. doi: 10.1038/322470a0.
7
Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein.针对重组包膜糖蛋白的抗体对艾滋病逆转录病毒的中和作用。
Science. 1986 Jul 11;233(4760):209-12. doi: 10.1126/science.3014647.
8
Identification of conserved and divergent domains within the envelope gene of the acquired immunodeficiency syndrome retrovirus.获得性免疫缺陷综合征逆转录病毒包膜基因中保守和差异结构域的鉴定。
Proc Natl Acad Sci U S A. 1986 Jul;83(14):5038-42. doi: 10.1073/pnas.83.14.5038.
9
HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex.艾滋病及艾滋病相关综合征患者体内的人嗜T淋巴细胞病毒III型中和抗体
Nature. 1985;316(6023):72-4. doi: 10.1038/316072a0.
10
Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients.艾滋病患者及有艾滋病风险患者的血清对人类Ⅲ型嗜T淋巴细胞病毒的中和作用。
Nature. 1985;316(6023):69-72. doi: 10.1038/316069a0.
Zotero 插件